Viking Therapeutics Stock Forecast

Stock Price Forecast

According to 20 analysts polled by S&P Global, Viking Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $92.58. The average 1-year stock price forecast is 154.55% higher than the current stock price, while the lowest is $34 (-6.52%) and the highest is $125 (+243.69%).

Price Target: $92.58 (+154.55%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$34	$92.58	$95	$125
Change	-6.52%	+154.55%	+161.20%	+243.69%

Analyst Ratings

The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	12	12	12	13	13	13
Buy	5	5	5	5	5	5
Hold	1	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	18	19	19	20	20	20

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andy Hsieh William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jul 16, 2026
Edward Nash Canaccord Genuity	Canaccord Genuity	Buy Maintains $107	Buy	Maintains	$107	+194.20%	Jul 15, 2026
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $71	Buy	Maintains	$71	+95.22%	Jul 7, 2026
Steven Seedhouse Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $100	Buy	Maintains	$100	+174.95%	Jul 1, 2026
Naz Rahman Maxim Group	Maxim Group	Buy Reiterates $70	Buy	Reiterates	$70	+92.47%	Jun 25, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-4.72

from -3.19

EPS Next Year

-4.57

from -4.72

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-55.68M	-70.36M	-100.83M	-150.92M	-393.34M	-590.13M
Net Income	-54.99M	-68.87M	-85.90M	-109.96M	-359.64M	-562.99M
EPS	-	-	-	-	-3.19	-4.72
Free Cash Flow	-32.16M	-25.22M	-42.36M	-55.58M	-160.22M	-570.86M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-3.81
Avg	-4.72
Low	-5.72

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-